Přirozená historie monoklonální lymfocytózy B buněk (MBL), chronické lymfocytární leukémie/lymfomu z malých lymfocytů (CLL/SLL), lymfoplazmocytárního lymfomu (LPL)/Waldenstromovy makroglobulinémie (WM) a lymfomu okrajové zóny sleziny (SMZL)

The purpose of this protocol is to collect blood, tissue (bone marrow and lymph node biopsies) and/or imaging studies (PET and CT scans) from patients with monoclonal B cell lymphocytosis (MBL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL).

Assessments will be used for clinical and translational research investigating the molecular basis of MBL, CLL/SLL, LPL/WM, SMZL and their clinical manifestations. New technologies now permit the simultaneous characterization of pathogenic events ranging from the control of gene expression to the characterization of the molecular events of cell-cell interactions. Applying these methods to MBL/CLL/SLL/LPL/WM/SMZL in the context of a natural history protocol can help unravel cellular pathways involved in pathogenesis and disease progression and lead to the discovery or the validation of therapeutic targets. MBL/CLL/SLL/LPL/WM/SMZL is an incurable disease for which there are no reliable cell lines and only a few mouse models. There is an urgent need to obtain a flow of primary samples to advance research into pathogenesis and novel treatment approaches.

Eligibility:

• Diagnosis of MBL/CLL/SLL/LPL/WM/SMZL
• Age greater than or equal to 18 years.
• ECOG performance status of 0-2.
• Design:

Patients will be typically followed every 6-12 months for the first 2 years and every 12-24 months thereafter. Interim visits may occur at the discretion of the research team. Patients may donate cellular products or tissues as appropriate for research purposes. Clinical information will be obtained and stored in a central databank.

• Objectives:

  • Describe the history of MBL/CLL/SLL/WM/SMZL in patients prior to and after treatment.
  • Apply the expertise and available technologies of the investigators to advance our understanding of disease pathogenesis by studying MBL/CLL/SLL and closely related B-cell malignancies, LPL/WM and SMZL
  • Develop novel treatment approaches for CLL/SLL/LPL/WM/SMZL.
  • Provide evaluation, diagnostic studies and monitoring for patients on study.
  • Provide blood and tissue linked to clinical and biologic information for translational studies.

• Endpoints:

  • Treatment-free survival, measured as the time from diagnosis or last therapy to the development of active disease that requires treatment at which time patients will be evaluated for a treatment protocol or seek treatment outside of NIH.